Literature DB >> 12417659

Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein.

Bridget Allen1, Esther Ingram, Masaki Takao, Michael J Smith, Ross Jakes, Kanwar Virdee, Hirotaka Yoshida, Max Holzer, Molly Craxton, Piers C Emson, Cristiana Atzori, Antonio Migheli, R Anthony Crowther, Bernardino Ghetti, Maria Grazia Spillantini, Michel Goedert.   

Abstract

The identification of mutations in the Tau gene in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) has made it possible to express human tau protein with pathogenic mutations in transgenic animals. Here we report on the production and characterization of a line of mice transgenic for the 383 aa isoform of human tau with the P301S mutation. At 5-6 months of age, homozygous animals from this line developed a neurological phenotype dominated by a severe paraparesis. According to light microscopy, many nerve cells in brain and spinal cord were strongly immunoreactive for hyperphosphorylated tau. According to electron microscopy, abundant filaments made of hyperphosphorylated tau protein were present. The majority of filaments resembled the half-twisted ribbons described previously in cases of FTDP-17, with a minority of filaments resembling the paired helical filaments of Alzheimer's disease. Sarkosyl-insoluble tau from brains and spinal cords of transgenic mice ran as a hyperphosphorylated 64 kDa band, the same apparent molecular mass as that of the 383 aa tau isoform in the human tauopathies. Perchloric acid-soluble tau was also phosphorylated at many sites, with the notable exception of serine 214. In the spinal cord, neurodegeneration was present, as indicated by a 49% reduction in the number of motor neurons. No evidence for apoptosis was obtained, despite the extensive colocalization of hyperphosphorylated tau protein with activated MAP kinase family members. The latter may be involved in the hyperphosphorylation of tau.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12417659      PMCID: PMC6758022     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  243 in total

Review 1.  Are tangles as toxic as they look?

Authors:  Tara L Spires-Jones; Katherine J Kopeikina; Robert M Koffie; Alix de Calignon; Bradley T Hyman
Journal:  J Mol Neurosci       Date:  2011-06-03       Impact factor: 3.444

2.  SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease.

Authors:  Pablo Garcia-Reitböck; Oleg Anichtchik; Arianna Bellucci; Mariangela Iovino; Chiara Ballini; Elena Fineberg; Bernardino Ghetti; Laura Della Corte; PierFranco Spano; George K Tofaris; Michel Goedert; Maria Grazia Spillantini
Journal:  Brain       Date:  2010-06-09       Impact factor: 13.501

3.  Neurodegenerative tauopathy in the worm.

Authors:  Michel Goedert
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-11       Impact factor: 11.205

Review 4.  Tau-targeted treatment strategies in Alzheimer's disease.

Authors:  Jürgen Götz; Arne Ittner; Lars M Ittner
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

5.  Neurogenesis in Alzheimer´s disease: a realistic alternative to neuronal degeneration?

Authors:  Rocío E Gonzalez-Castaneda; Alma Y Galvez-Contreras; Sonia Luquín; Oscar Gonzalez-Perez
Journal:  Curr Signal Transduct Ther       Date:  2011-09-01

6.  Amyloid precursor protein and tau transgenic models of Alzheimer's disease: insights from the past and directions for the future.

Authors:  Naruhiko Sahara; Jada Lewis
Journal:  Future Neurol       Date:  2010-05-01

7.  Activity-Dependent Reconnection of Adult-Born Dentate Granule Cells in a Mouse Model of Frontotemporal Dementia.

Authors:  Julia Terreros-Roncal; Miguel Flor-García; Elena P Moreno-Jiménez; Noemí Pallas-Bazarra; Alberto Rábano; Nirnath Sah; Henriette van Praag; Damiana Giacomini; Alejandro F Schinder; Jesús Ávila; Maria Llorens-Martín
Journal:  J Neurosci       Date:  2019-05-27       Impact factor: 6.167

8.  Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach.

Authors:  Laetitia Troquier; Raphaelle Caillierez; Sylvie Burnouf; Francisco J Fernandez-Gomez; Marie-Eve Grosjean; Nadege Zommer; Nicolas Sergeant; Susanna Schraen-Maschke; David Blum; Luc Buee
Journal:  Curr Alzheimer Res       Date:  2012-05       Impact factor: 3.498

Review 9.  Novel Key Players in the Development of Tau Neuropathology: Focus on the 5-Lipoxygenase.

Authors:  Elisabetta Lauretti; Domenico Praticò
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

10.  Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: implication for Alzheimer disease.

Authors:  Zhi Tang; Erika Bereczki; Haiyan Zhang; Shan Wang; Chunxia Li; Xinying Ji; Rui M Branca; Janne Lehtiö; Zhizhong Guan; Peter Filipcik; Shaohua Xu; Bengt Winblad; Jin-Jing Pei
Journal:  J Biol Chem       Date:  2013-04-12       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.